Jennifer Pennock, MD
Endocrinology, Diabetes & Metabolism · Wexford, PANPI 1962475681
Payments from drug & device makers
Across 73 payments — averaging $19.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$395
- AstraZeneca$146
- Lilly USA, LLC$110
- Medtronic$87
- Dexcom, Inc.$72
- Sanofi-aventis U.S. LLC$70
- plus $522 from 18 others
What the payments were for
- Food & beverage$1,19685%
- Education$20615%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 25 | $395 |
| AstraZeneca(2 entities) | 4 | $146 |
| Lilly USA, LLC | 5 | $110 |
| Medtronic | 3 | $87 |
| Dexcom, Inc. | 3 | $72 |
| Sanofi-aventis U.S. LLC | 4 | $70 |
| Abbott | 3 | $62 |
| Amgen | 3 | $58 |
| Bayer | 3 | $56 |
| Corcept Therapeutics | 3 | $49 |
| Xeris Pharmaceuticals, Inc. | 3 | $46 |
| Embecta Corp. | 2 | $42 |
| Amneal Pharmaceuticals LLC | 1 | $28 |
| BD | 1 | $21 |
| QOL Medical, LLC | 1 | $20 |
| Mannkind Corporation | 1 | $19 |
| Lifescan, Inc. | 1 | $19 |
| Radius Health, Inc. | 1 | $18 |
| Kyowa Kirin, Inc. | 1 | $17 |
| Sequel Med Tech, LLC | 1 | $16 |
| Ascendis Pharma Endocrinology Inc | 1 | $16 |
| Alfasigma USA, Inc. | 1 | $14 |
| Boehringer Ingelheim | 1 | $14 |
| Cequr Corporation | 1 | $5 |
How this compares
$1,402 in reported general payments places this provider in the 50th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
See all endocrinology, diabetes & metabolism providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 434 | $562,320 |
| MounjaroTirzepatide | 275 | $325,436 |
| JardianceEmpagliflozin | 285 | $315,347 |
| TrulicityDulaglutide | 196 | $229,011 |
| FarxigaDapagliflozin Propanediol | 159 | $171,606 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 73 | $112,053 |
| Tresiba Flextouch U-200Insulin Degludec | 49 | $79,191 |
| Tresiba Flextouch U-100Insulin Degludec | 91 | $62,551 |
| RybelsusSemaglutide | 23 | $53,216 |
| ForteoTeriparatide | 11 | $42,572 |
| Novolog FlexpenInsulin Aspart | 125 | $39,361 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 54 | $38,542 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $35,686 |
| JanuviaSitagliptin Phosphate | 25 | $26,845 |
| ProliaDenosumab | 15 | $25,353 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $395 | $621,162471 claims |
| Lilly USA, LLCMounjaro, Trulicity, Forteo, Humalog | $110 | $601,718493 claims |
| Boehringer IngelheimJardiance | $14 | $315,347285 claims |
| AstraZenecaFarxiga | $146 | $171,606159 claims |
| AmgenProlia | $58 | $25,35315 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $28 | $3,001387 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
Other endocrinology, diabetes & metabolism in Wexford
- Mona Al MukaddamPhiladelphia$3.9M
- Serge JabbourPhiladelphia$3.1M
- Mihaela BiscoveanuPhiladelphia$1.5M
- Barbara SimonPhiladelphia$1M
- Mitchell LazarPhiladelphia$1M
- Vijay BahlPittsburgh$998K
- Intekhab AhmedPhiladelphia$926K
- Erin KershawPittsburgh$804K
- Geraldo SaavedraWhitehall$698K
- Arvind CavaleFeasterville Trevose$662K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.